NASDAQ:ADPT

Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis

Adaptive Biotechnologies logo
$27.90 -0.15 (-0.53%)
Closing price 03:58 PM Eastern
Extended Trading
$27.93 +0.03 (+0.11%)
As of 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Adaptive Biotechnologies Stock (NASDAQ:ADPT)

Advanced

Key Stats

Today's Range
$27.15
▼
$28.23
50-Day Range
$23.95
▼
$30.26
52-Week Range
$12.00
▼
$32.21
Volume
2.48 million shs
Average Volume
2.30 million shs
Market Capitalization
$4.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.31
Consensus Rating
Moderate Buy

Company Overview

Adaptive Biotechnologies is a biotechnology company focused on using the human immune system to diagnose and treat disease. Based in Seattle, Washington, the company develops technologies that sequence and analyze immune cells and their receptors, generating data for clinical testing, research and drug development.

Its products include immunoSEQ, a platform used by researchers and biopharmaceutical companies to study immune responses, and clonoSEQ, a clinical test that detects and monitors minimal residual disease in certain blood cancers. Adaptive also works with pharmaceutical and biotechnology partners to apply its immune-sequencing capabilities to therapeutic research and development.

Founded in 2009, Adaptive was co-founded by brothers Chad and Harlan Robins. Chad Robins has served as the company’s chief executive officer. The company works with customers and partners in clinical and research settings, including through collaborations that extend beyond the United States.

AI Generated. May Contain Errors.

Adaptive Biotechnologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

ADPT MarketRank™: 
2.386924342105 of 5 stars

Adaptive Biotechnologies scored higher than 48% of companies evaluated by MarketBeat, and ranked 566th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Adaptive Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Adaptive Biotechnologies has a consensus price target of $30.31, representing about 10.3% upside from its current price of $27.49.

  • Amount of Analyst Coverage

    Adaptive Biotechnologies has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Adaptive Biotechnologies' stock forecast and price target.
  • Earnings Growth

    Earnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($0.24) to ($0.03) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Adaptive Biotechnologies is -61.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Adaptive Biotechnologies is -61.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Adaptive Biotechnologies has a P/B Ratio of 24.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Adaptive Biotechnologies' valuation and earnings.
  • Percentage of Shares Shorted

    7.52% of the float of Adaptive Biotechnologies has been sold short.
  • Short Interest Ratio / Days to Cover

    Adaptive Biotechnologies has a short interest ratio ("days to cover") of 6.07.
  • Change versus previous month

    Short interest in Adaptive Biotechnologies has recently decreased by 4.28%, indicating that investor sentiment is improving.
  • Dividend Yield

    Adaptive Biotechnologies does not currently pay a dividend.

  • Dividend Growth

    Adaptive Biotechnologies does not have a long track record of dividend growth.

  • News Sentiment

    Adaptive Biotechnologies has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Adaptive Biotechnologies this week, compared to 6 articles on an average week.
  • Search Interest

    12 people have searched for ADPT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,380,755.00 in company stock.

  • Percentage Held by Insiders

    5.70% of the stock of Adaptive Biotechnologies is held by insiders.

  • Percentage Held by Institutions

    99.17% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Adaptive Biotechnologies' insider trading history.
Receive ADPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ADPT Stock News Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Headlines

ADPT Stock Analysis - Frequently Asked Questions

Adaptive Biotechnologies' stock was trading at $16.24 at the beginning of the year. Since then, ADPT shares have increased by 69.2% and is now trading at $27.4850.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) released its earnings results on Wednesday, November, 4th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.12. The firm's revenue for the quarter was down 10.7% compared to the same quarter last year.
Read the conference call transcript
.

Adaptive Biotechnologies (ADPT) raised $278 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 15,000,000 shares at a price of $18.00-$19.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

Adaptive Biotechnologies' top institutional shareholders include State Street Corp (2.20%), Goldman Sachs Group Inc. (1.91%), Sumitomo Mitsui Trust Group Inc. (0.68%) and First Trust Advisors LP (0.49%). Insiders that own company stock include Chad M Robins, Harlan S Robins, Tycho Peterson, Susan Bobulsky, Julie Rubinstein, Kyle Piskel, Sharon Benzeno, Francis Lo, Stacy L Taylor, Peter M Neupert, Michelle Renee Griffin and Robert Hershberg.
View institutional ownership trends
.

Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptive Biotechnologies investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Block (XYZ), Palantir Technologies (PLTR), Micron Technology (MU) and CRISPR Therapeutics (CRSP).

Company Calendar

Last Earnings
11/04/2026
Today
11/20/2026
38th Annual Healthcare Conference
12/02/2026
Fiscal Year End
12/31/2026
Next Earnings (Estimated)
2/04/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:ADPT
CIK
1478320
Employees
624
Year Founded
2009

Price Target and Rating

High Price Target
$35.00
Low Price Target
$19.00
Potential Upside/Downside
+8.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.45)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$59.50 million
Net Margins
-23.67%
Pretax Margin
-23.73%
Return on Equity
-23.95%
Return on Assets
-8.01%

Debt

Debt-to-Equity Ratio
1.82
Current Ratio
3.97
Quick Ratio
3.87

Sales & Book Value

Annual Sales
$276.98 million
Price / Sales
16.31
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.14 per share
Price / Book
24.47

Miscellaneous

Outstanding Shares
161,880,000
Free Float
152,650,000
Market Cap
$4.52 billion
Optionable
Optionable
Beta
2.18

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:ADPT) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners